AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Metachromatic Leukodystrophy

Recent research efforts aimed at curing Metachromatic Leukodystrophy.

Last updated

Metachromatic Leukodystrophy

Overview

Metachromatic leukodystrophy (MLD) is a rare inherited disorder in which changes in both copies of the ARSA gene leave the body short of arylsulfatase A (ARSA), an enzyme needed to break down fatty molecules called sulfatides. Sulfatides then accumulate in the brain, spinal cord, and peripheral nerves, damaging myelin—the insulating coating that helps nerves send signals—and causing progressive loss of movement, thinking, speech, swallowing, and other functions. GeneReviews: Arylsulfatase A Deficiency Libmeldy EPAR

MLD can begin in infancy, childhood, or adulthood, but the late-infantile and early-juvenile forms are usually the fastest progressing and can lead to profound disability and early death without effective early intervention. Care still includes multidisciplinary symptom management—nutrition, physical and occupational therapy, treatment of seizures and spasticity, respiratory support, and family support—but disease-modifying treatment is now available for selected children before, or very early in, neurologic decline. In the United States, the standard targeted option for eligible early-onset cases is the one-time autologous blood-stem-cell gene therapy atidarsagene autotemcel (Lenmeldy); donor hematopoietic stem-cell transplantation remains a consideration mainly for carefully selected later-onset patients with no or minimal disease involvement. Consensus guidelines for MLD in the United States LENMELDY prescribing information

Scope of Recent Research (2020–present)

Research since 2020 has shifted MLD from a disease with mainly supportive care toward one in which early genetic correction can substantially alter the course of early-onset disease. The dominant questions are now how to identify children before irreversible neurologic injury, make treatment safer and more accessible, extend benefit to children who already have symptoms, and develop direct brain-targeted therapies that could reach cells more quickly. The field has an approved therapy with long-term benefit in a defined population, but it is not yet a proven lifelong cure for all MLD forms or for children with advanced disease. Long-Term Effects of Atidarsagene Autotemcel Newborn Screening for MLD: Systematic Review

Major Breakthroughs and Emerging Therapies

The major breakthrough is ex vivo hematopoietic stem-cell gene therapy with atidarsagene autotemcel, also called arsa-cel and marketed as Libmeldy in Europe and Lenmeldy in the United States. Doctors collect a child’s own CD34-positive blood-forming stem cells, insert a working ARSA gene using a lentiviral vector, give chemotherapy conditioning to make room in the bone marrow, and infuse the corrected cells back. These cells and their descendants produce ARSA, including myeloid cells that can enter the nervous system and help reduce sulfatide storage. The European Union authorized Libmeldy in December 2020, and the FDA approved Lenmeldy on March 18, 2024, for presymptomatic late-infantile MLD, presymptomatic early-juvenile MLD, and early-symptomatic early-juvenile MLD. Libmeldy EPAR FDA LENMELDY product page

Long-term clinical evidence strengthened the case for this strategy in 2025. In two prospective open-label studies and expanded-access programs, 39 treated patients were compared with 49 untreated natural-history patients, with a median follow-up of 6.76 years. Among children with presymptomatic late-infantile disease, the estimated proportion alive without severe motor impairment at age six was 100% after treatment versus 0% in untreated comparators; treated presymptomatic and early-symptomatic early-juvenile groups also had substantially better motor-survival estimates than untreated comparators. No insertional cancers were found in this cohort, although follow-up must continue. Long-Term Effects of Atidarsagene Autotemcel

Gene editing is a promising but preclinical alternative. A 2022 study used CRISPR-Cas9 with an AAV6 DNA repair template to place a functional ARSA sequence at the native ARSA site in human blood stem and progenitor cells. In cells from two people with different MLD mutations, the approach restored ARSA activity to levels comparable with healthy-adult cells, without detectable off-target edits in the reported experiments. This “mutation-agnostic” design could theoretically serve many different ARSA mutations, but it has not yet been tested clinically in MLD. Mutation-Agnostic HSC Gene Therapy for MLD

In vivo gene therapy, in which a vector is injected directly into the body rather than modifying cells outside it, aims to treat the central nervous system more rapidly and potentially reach patients who are already symptomatic. In an Arsa-knockout mouse model, intravenous delivery of an AAV-PHP.eB vector carrying human ARSA broadly transduced the brain and spinal cord, corrected measured sulfatide storage, and improved markers of neuroinflammation, including when administered later in symptomatic mice. These results justify further development, but they remain mouse data: vector behavior, immune responses, dose, and safety may differ substantially in people. Intravenous AAV Gene Therapy in Symptomatic MLD Mice

Enzyme replacement therapy remains an experimental complementary strategy rather than a cure. Recombinant human ARSA delivered into cerebrospinal fluid is intended to bypass the blood–brain barrier, but repeated dosing and the need to demonstrate meaningful preservation of motor and cognitive function remain major obstacles. Earlier phase 1/2 intrathecal SHP611 studies primarily established safety and tolerability, while later studies have used motor-function and cerebrospinal-fluid sulfatide endpoints to test whether the enzyme can alter disease progression. Phase 1/2 Intrathecal rhASA Study SHP611-201 Phase II Trial

Clinical Trials and Experimental Approaches

The pivotal atidarsagene autotemcel program began as a phase 1/2 study at the San Raffaele Telethon Institute for Gene Therapy in Milan and enrolled presymptomatic late-infantile and pre- or early-symptomatic early-juvenile patients. The registered intervention was autologous CD34-positive cells transduced outside the body with a lentiviral vector encoding ARSA. Long-term results from this clinical-development program now provide the strongest evidence that early genetic correction can prevent or markedly delay severe motor deterioration in eligible children. NCT01560182: Gene Therapy for MLD Long-Term Effects of Atidarsagene Autotemcel

A separate phase II program evaluated intrathecal SHP611, a recombinant ARSA enzyme, in children with late-infantile MLD. The study was sponsored by Shire Human Genetic Therapies, with Takeda Development Center Americas listed as the funding source; it planned to compare time to loss of locomotion with an external control group and to measure cerebrospinal-fluid sulfatides. The CTIS record lists the trial as ended on May 9, 2026; its public summary describes the design and endpoints but does not provide efficacy results. SHP611-201 Phase II Trial

Methodologies and Scientific Approaches

Researchers combine natural-history cohorts with prospective single-arm studies because MLD is ultra-rare and rapidly progressive, making conventional placebo-controlled trials difficult and often ethically problematic. Key outcome measures include survival without severe motor impairment, the Gross Motor Function Classification in MLD scale, cognitive development, brain MRI measures of white-matter injury, ARSA activity, and sulfatides in blood, urine, or cerebrospinal fluid. Long-Term Effects of Atidarsagene Autotemcel SHP611-201 Phase II Trial

Preclinical programs use patient-derived blood stem cells, gene-edited cells, and Arsa-deficient mouse models to test enzyme restoration, vector distribution, sulfatide clearance, neuroinflammation, and toxicology before human trials. Delivery-platform research compares lentiviral modification of autologous stem cells with AAV vectors designed for systemic or direct central-nervous-system delivery. Mutation-Agnostic HSC Gene Therapy for MLD Intravenous AAV Gene Therapy in Symptomatic MLD Mice

Leading Institutions and Funding

The leading clinical and translational center has been the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and IRCCS San Raffaele Scientific Institute in Milan, where the stem-cell gene-therapy platform was developed. Fondazione Telethon supported the initial clinical study through 2016, GlaxoSmithKline supported it from 2016 through 2018, and Orchard Therapeutics supported later clinical development; Orchard is the manufacturer named in the U.S. approval record. Long-Term Effects of Atidarsagene Autotemcel FDA LENMELDY product page

Other important contributors include University Hospital Tübingen, which has advanced CRISPR-based stem-cell editing research; the Institut du Cerveau/Sorbonne Université and collaborating French pediatric-neurology groups, which are advancing systemic AAV approaches; Takeda, which has funded intrathecal ARSA studies; and newborn-screening researchers and public-health programs in Europe and the United States. National newborn screening is already operating in Norway, while large prospective pilots have been reported in Germany, Austria, Italy, and the United States. Mutation-Agnostic HSC Gene Therapy for MLD Intravenous AAV Gene Therapy in Symptomatic MLD Mice Newborn Screening for MLD: Systematic Review

Strengths, Limitations, and Challenges

The central strength of atidarsagene autotemcel is that it addresses the root enzymatic defect with a single individualized treatment and has now shown multi-year benefit in the population most likely to respond: children treated before symptoms, or at the earliest stage of early-juvenile disease. The treatment also avoids donor-cell rejection and graft-versus-host disease because it uses the patient’s own cells. However, it cannot reliably reverse established loss of myelin or neurons, and evidence is limited for advanced early-onset disease, late-juvenile disease, and adult MLD. Long-Term Effects of Atidarsagene Autotemcel Consensus guidelines for MLD in the United States

Treatment itself is intensive. It requires stem-cell collection, specialized manufacturing, myeloablative chemotherapy, and care at an experienced transplant center. Important risks include severe infections during low blood-cell counts, liver complications, thrombosis, delayed engraftment, inflammation of the brain, and a theoretical long-term risk of insertional cancer from lentiviral gene insertion; the FDA label requires ongoing monitoring for hematologic malignancy. Access is also constrained by diagnostic delay, limited specialist-center capacity, manufacturing logistics, and the need for newborn screening to identify children while treatment can still prevent damage. LENMELDY prescribing information Newborn Screening and Presymptomatic Treatment of MLD

Outlook and Future Directions

As of October 23, 2026, MLD is closer to a functional cure for a subset of children than it was in 2020: early autologous stem-cell gene therapy can preserve meaningful motor function and survival in many appropriately selected patients. It is not yet a universal cure because treatment must occur before substantial neurologic injury, long-term durability beyond current follow-up remains under study, and effective options for symptomatic late-infantile, late-juvenile, and adult patients remain inadequate. The most important milestones to watch are wider implementation of newborn screening, continued long-term safety and durability data for Lenmeldy/Libmeldy, publication of intrathecal enzyme-therapy results, and translation of in vivo AAV and gene-editing approaches from animal and cell studies into carefully designed human trials. Long-Term Effects of Atidarsagene Autotemcel Newborn Screening for MLD: Systematic Review Intravenous AAV Gene Therapy in Symptomatic MLD Mice

References

Don't see your disease? Request a report